Adicet Bio, Inc. (ACET)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Chen Schor BA, CPA, M.B.A. | CEO, President & Director | 888.01k | -- | 1972 |
| Dr. Aya Jakobovits Ph.D. | Founder & Independent Director | 45k | -- | 1955 |
| Mr. Brian Nicholas Harvey | Chief Financial Officer | 611.14k | -- | 1961 |
| Dr. Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer | 693.82k | -- | 1981 |
| Dr. Donald Healey Ph.D. | Chief Technology Officer | 606.34k | -- | 1962 |
| Ms. Amy Locke | Chief Human Resource Officer | -- | -- | -- |
| Dr. Julie Maltzman M.D. | Chief Medical Officer | -- | -- | -- |
Adicet Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 152
Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Corporate Governance
Upcoming Events
August 11, 2025 at 12:30 PM UTC - August 15, 2025 at 12:30 PM UTC
Adicet Bio, Inc. Earnings Date
Recent Events
March 12, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission